canadian blood services is pleased to announce its summer 2020 blood efficiency accelerator program competition. the objective of the program is to improve the efficient and appropriate utilization of blood products, while maintaining the safety of the blood system.

read our blog post to learn more about the funding opportunity.

for detailed information about the blood efficiency accelerator program competition, please refer to www.blood.ca. the deadline to submit completed application packages is july 17 2020.

canadian blood services is pleased to announce its 2020 postdoctoral fellowship program competition. through this program, canadian blood services offers salary support to young investigators training in a canadian research laboratory affiliated with canadian blood services.

read our blog post to learn more about the funding opportunity.

for detailed information about the postdoctoral fellowship program competition, please refer to www.blood.ca. the deadline to submit completed application packages is july 17 2020.

the canada council for the arts can help propel the careers of outstanding researchers through its prestigious killam prizes. there is still time to nominate a candidate!

five (5) prizes are awarded annually – one in each of the disciplines of engineering, health sciences, humanities, natural sciences, and social sciences. these career achievement awards recognize substantial and distinguished contribution, over a significant period, to scholarly research.

value: $100,000 each
how to qualify: nominate a candidate to the canada council for the arts
deadline: 30 june, 2020
for further information: see the guidelines

up to $10,000 in one-year project funding to support small budget proposals on projects researching the history of medicine and healthcare that strive to advance the history of health, healthcare and disease, or the education of health professionals.

up to $45,000 in funding to support emerging scholars complete projects featuring the study, analysis, and interpretation of past practices, philosophies, and/or epistemologies related to human health, healthcare, and/or disease or the education of health professionals.

$25,000 to support full-time doctoral 世界杯2022赛程表淘汰赛 in the humanities or social sciences complete their dissertation on a history of medicine/healthcare topic.

about the award

the career awards for medical scientists (cams) is a highly competitive program that provides $700,000 awards over five years for physician-scientists, who are committed to an academic career, to bridge advanced postdoctoral/fellowship training and the early years of faculty service. 

details

proposals must be in the area of basic biomedical, disease-oriented, or translational research.  proposals in health services research or involving large-scale clinical trials are not eligible. the previously funded individuals (or researchers) are listed in the grant recipients section of this program.

idrc and the swedish international development cooperation agency (sida) are contributing up to ca$10 million towards a covid-19 global south artificial intelligence and data innovation program. the program aims to support multidisciplinary research to deepen understanding of how to develop and scale responsible (inclusive, rights-based, ethical, and sustainable) evidence-based artificial intelligence (ai) and data science approaches that support covid-19 response and recovery in low- and middle-income countries (lmics).

specifically, the program will aim to support research that is linked to government responses in the following areas:

• forecasting transmissions and reducing spread through policy and public health interventions;
• optimizing public health system responses for patient diagnosis, care, and management;
• mobilizing ai and data science to understand and support gender inclusive covid-19 action;
• building trust and combatting mis- and dis-information around covid-19;
• strengthening data systems and information sharing about covid-19; and
• supporting transparent and responsible ai, data, and digital rights governance around covid-19 and pandemic responses.

the fy20 defense appropriations act provides funding to the department of defense kidney cancer research program (kcrp) to support research of exceptional scientific merit in the area of kidney cancer.  as directed by the office of the assistant secretary of defense for health affairs, the defense health agency j9, research and development directorate manages the defense health program (dhp) research, development, test, and evaluation (rdt&e) appropriation.  the managing agent for the anticipated program announcements/funding opportunities is the congressionally directed medical research programs (cdmrp) at the u.s. army medical research and development command (usamrdc).

the fy20 kcrp program announcements and general application instructions for the following award mechanisms are posted on the grants.gov website. 

applications submitted to the fy20 kcrp idea development award mechanism are encouraged to address one or more of the following areas of emphasis:

• treatments/survivorship
• basic/translational science
• diagnostics/prognostics/biomarkers/surveillance
• population-based studies

• noninvasive interventions
• surgical interventions
• therapeutic development
• understanding and managing toxicity
• survivorship and patient experience

• genetics
• chromatin and gene regulation
• metabolism
• microenvironment and immunology
• environmental exposures (and/or deployment-related exposures)
• new disease model systems
• rare kidney cancers
• mechanism of response and resistance

• prognosis
• biomarker development
• novel imaging technologies
• liquid biopsy
• microbiome
• disease disparities

• screening and early detection
• surveillance
• outcome/population-based studies
• environmental exposures (and/or deployment-related exposures)
• disease disparities

https://cdmrp.army.mil/funding/kcrp

clinical consortium award – letter of intent due september 2, 2020

independent investigators at or above the level of assistant professor (or equivalent)

• supports the expansion of a consortium that will facilitate rapid execution of collaborative clinical trials that will bring to market high-impact, novel therapeutics that will ultimately and significantly decrease impact of kidney cancer
• funds may not be used for research or development of clinical protocols
• trials that incorporate investigations of biomarkers for risk assessment, early detection, prediction of aggressiveness, and/or progression of kidney cancer are encouraged
• up to two (2) clinical trial sites will be selected and be jointly responsible for proposing, selecting, and conducting trials within the existing kidney cancer research consortium
• sites must provide plans for accruing patients from populations disproportionately affected by kidney cancer
• the consortium is expected to achieve financial self-sufficiency, such that operating can continue after the award period ends.
  • maximum funding of $600,000 for direct costs (plus indirect costs)
  • maximum period of performance 2 years
  • indirect costs may be proposed in accordance with the institution’s negotiated rate agreement

idea development award - letter of intent due september 2, 2020

established investigators: 

independent investigators at or above the level of assistant professor (or equivalent) and 10 years or more from a terminal degree

early career investigators:

investigators at the level of assistant professor, instructor, or assistant research professor (or equivalent) and less than 10 years from a terminal degree (excluding time spent in medical residency or family medical leave) at the time of application submission deadline are eligible

• supports new ideas that represent innovative, high-risk/high-gain approaches to kidney cancer research, and have the potential to make an important contribution to kidney cancer
• innovation and impact are the most important review criteria
• different funding options, based on the scope of the proposed research, are available with compelling justification.
• preliminary data are required.
• clinical trials not allowed

early detection studies option:

• maximum funding of $650,000 in direct costs (plus indirect costs)
• maximum period of performance 3 years
• indirect costs may be proposed in accordance with the institution’s negotiated rate agreement

population science and prevention studies option:

• maximum funding of $2 million in direct costs (plus indirect costs)
• maximum period of performance 4 years
  • indirect costs may be proposed in accordance with the institution’s negotiated rate agreement

postdoctoral and clinical fellow award – letter of intent due september 2, 2020

must have completed requirements for ph.d. and/or m.d.

must be in the laboratory or clinical setting where proposed research will be performed.

must have no more than 4 years of postdoctoral and/or mentored clinical research experience

investigators in non-postdoctoral and/or clinical fellow positions are not eligible.

• supports research opportunities focused on kidney cancer for individuals in the early stages of their careers
• a designated mentor who is an experienced kidney cancer researcher is required.
• clinical trials are not allowed.
  • maximum funding of $195,000 for direct costs (plus indirect costs)
  • maximum period of performance 3 years
    • indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

a pre-application is required and must be submitted through the electronic biomedical research application portal (ebrap) at https://ebrap.org prior to the pre-application deadline.  all applications must conform to the final program announcements and general application instructions available for electronic downloading from the grants.gov website.  the application package containing the required forms for each award mechanism will also be found on grants.gov.  a listing of all cdmrp and other usamrdc extramural funding opportunities can be obtained on the grants.gov website by performing a basic search using cfda number 12.420.

submission deadlines are not available until the program announcements are released.  for email notification when program announcements are released, subscribe to program-specific news and updates under “email subscriptions” on the ebrap homepage at https://ebrap.org.  for more information about the kcrp or other cdmrp-administered programs, please visit the cdmrp website (https://cdmrp.army.mil).

point of contact:

cdmrp help desk
301-682-5507
help@ebrap.org

the health research foundation of innovative medicines canada invites applications for the health research foundation of innovative medicines canada chair in pandemic preparedness research.

the member companies of innovative medicines canada contributed $500,000 to support the work of an early-career researcher affiliated with a recognized canadian academic institution through the creation of a research chair in pandemic preparedness. innovative medicines canada recognizes the critical need to support research excellence and to help world-class scientists working on the discoveries and innovations that keep us and our communities healthy, and our economy thriving. the creation of a research chair dedicated to pandemic preparedness, as well as to the role of healthcare and the healthcare sector in sustaining and growing our economy, will contribute to helping canada look ahead to the next public health crisis and ensure our country is well-prepared to effectively respond and recover.